RxDoctor Payments Data

Kristina Harrington, MD

Child & Adolescent Psychiatry · Boise, IDNPI 1407887623

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 12 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Johnson & Johnson at 25.9% of the total.

$210in general payments, 2019–2025

Across 12 payments — averaging $17.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$55
  • Alkermes, Inc.$38
  • Indivior Inc.$37
  • Otsuka America Pharmaceutical, Inc.$36
  • Teva Pharmaceuticals USA, Inc.$20
  • Supernus Pharmaceuticals, Inc.$17
  • plus $8 from 1 others

What the payments were for

  • Food & beverage$210100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few child & adolescent psychiatry providers in Idahoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$115,921
Medicare patients
203
Services billed
1,318

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Paliperidone ErPaliperidone23$16,236
Lurasidone Hcl13$6,577
ZubsolvBuprenorphine Hcl/Naloxone Hcl16$5,905
RisperdalRisperidone13$5,849
Divalproex Sodium ErDivalproex Sodium48$3,972
Quetiapine Fumarate73$1,275
Modafinil19$1,144
Haloperidol17$1,100
Duloxetine Hcl37$978
Bupropion XlBupropion Hcl47$960
Lamotrigine85$780
Aripiprazole41$770
Guanfacine Hcl16$688
Venlafaxine Hcl ErVenlafaxine Hcl47$582
Trazodone Hcl88$429

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonRisperdal$55$5,84913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few child & adolescent psychiatry providers in Idahoon file to place this against a meaningful peer group, so we don't.

Other child & adolescent psychiatry in Boise

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →